1. HNSCCs overexpressing wild-type HRAS are sensitive to combined tipifarnib and alpelisib treatment. (October 2022) Authors: Soifer, H.; Mishra, V.; Malik, S.; Smith, A.; Chan, S.; Kessler, L.; Burrows, F.; Leoni, M.; Saunders, A.; Dale, S. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S58 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗